Day Lucy 4

What Happened

• Lucy Day, Chief Financial Officer of AN2 Therapeutics (ANTX), was granted 38,000 restricted stock units (RSUs) effective Feb 20, 2026 (acquired at $0.00). The same report also shows a derivative disposition of 77,000 shares (reported at $0.00). These entries are reported as awards/grants and a derivative transaction rather than an open-market buy or sale.

Key Details

• Transaction date(s): Feb 20, 2026; Form 4 filed Feb 23, 2026 (timely filing).
• Grant: 38,000 RSUs acquired, price reported $0.00.
• Derivative disposition: 77,000 units reported as disposed, price reported $0.00 (filing does not state reason for disposition).
• Shares owned after transaction: not specified in the excerpt of the filing provided.
• Notable footnotes:
  • F1: The 38,000 RSUs vest 25% annually over four years starting Jan 1, 2026, subject to continued service.
  • F2: Includes earlier RSU balances: 27,500 RSUs (vest starting Jan 1, 2024) and 46,500 RSUs (vest starting Jan 1, 2025), each vesting 1/4 annually subject to service.
  • F3: Adjusted total includes 5,000 shares purchased under the 2022 ESPP on Mar 31, 2025.
  • F4: Option grants (if any) vest monthly (1/48th) over four years from Jan 1, 2026.
• No 10b5-1 plan, tax-withholding sale, or late-filing flag is indicated in the provided details.

Context

• This filing primarily records compensation-related awards (RSUs). Grants are common executive compensation and do not represent an open-market purchase (a stronger bullish signal) or a sale.
• The 77,000-share "derivative disposition" is reported at $0.00; the form excerpt does not explain whether that reflects conversion, cancellation, exercise settlement, or another administrative action.